LDH: Monoclonal antibody treatments paused due to federal decision as Omicron variant shows resistance

Louisiana News

BATON ROUGE, La. (BRPROUD) — The Louisiana Department of Health (LDH) has announced that monoclonal antibody treatments at LDH-run sites will be paused due to a federal decision to stop state allocations.

According to LDH, recent data shows that two treatments offered, REGEN-COV and bamlanivimab and etesevimab (administered together), are not effective against Omicron.

“As a result, the federal government paused further allocations of these monoclonal antibodies pending updated data from the Centers for Disease Control and Prevention (CDC),” stated LDH in a news release.

Monoclonal antibody treatment, sotrovimab, has shown to remain effective against the new variant, according to LDH, and allocations of sotrovimab should be expected in January.

“Limited doses of sotrovimab have been distributed to the following select hospitals across the state,” said LDH officials. “However, the treatment will be in scarce supply until new deliveries arrive. As supply becomes more widely available, LDH will be ready to reopen sites when there a sufficient allocation for hospitals and community sites.”

LDH says the following hospitals will have sotrovima upon delivery:

  • North Oaks Medical Center, 15790 Paul Vega MD Drive, Hammond
  • Ochsner Medical Center, 1514 Jefferson Drive, New Orleans
  • Our Lady of the Lake Regional Medical Center, 5000 Hennessy Blvd., Baton Rouge
  • St. Francis Medical Center, 609 Jackson St., Monroe
  • University Medical Center, 2000 Canal St., New Orleans
  • Lake Charles Memorial Hospital, 1701 Oak Park Blvd., Lake Charles

LDH continues to advise residents to get vaccinated and take precautions during the holiday.

Copyright 2022 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Latest BRProud Articles

More Local News

Stay up to date with the latest news by downloading the BRProud App from the App Store or Google Play.

Trending Stories